Genetics and Pathogenesis of Diffuse Large B-Cell LymphomaRoland Schmitz, Louis M. Staudt, Wenming Xiao et al.|New England Journal of Medicine|2018Cited by 2.3k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory CommitteeElı́as Campo, Andrew D. Zelenetz, Ari Melnick et al.|Blood|2022Cited by 1.5k
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityWyndham H. Wilson, Rod Humerickhouse, Owen A. O’Connor et al.|The Lancet Oncology|2010Cited by 852
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaJohn P. Leonard, Geoffrey I. Shapiro|Blood|2012Cited by 297
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Chaitra S. Ujjani, Bruce D. Cheson, Sin‐Ho Jung et al.|Blood|2016Cited by 59